Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Immuneering (IMRX) Gross Profit (2020 - 2022)

Immuneering's Gross Profit history spans 3 years, with the latest figure at $455.0 for Q4 2022.

  • On a quarterly basis, Gross Profit rose 102.74% to $455.0 in Q4 2022 year-over-year; TTM through Sep 2023 was $455.0, a 99.68% decrease, with the full-year FY2022 number at $158830.0, down 82.86% from a year prior.
  • Gross Profit came in at $455.0 for Q4 2022, down from $19037.0 in the prior quarter.
  • The five-year high for Gross Profit was $367568.0 in Q3 2020, with the low at -$16630.0 in Q4 2021.
  • Historically, Gross Profit has averaged $171718.7 across 3 years, with a median of $191847.0 in 2020.
  • Biggest five-year swings in Gross Profit: plummeted 108.67% in 2021 and later soared 102.74% in 2022.
  • Year by year, Gross Profit stood at $191847.0 in 2020, then tumbled by 108.67% to -$16630.0 in 2021, then surged by 102.74% to $455.0 in 2022.
  • Business Quant data shows Gross Profit for IMRX at $455.0 in Q4 2022, $19037.0 in Q3 2022, and $46486.0 in Q2 2022.